The group's principal activities are to develop and market innovative products for the treatment of serious pulmonary and infectious diseases and cancer. The group marketed three products; actimmune, infergen and amphotec. Actimmune is approved in the United States for two rare congenital disorders. Infergen is marketed in the United States and Canada for the treatment of chronic hepatitis c infections. Amphotec is marketed worldwide for the treatment of invasive aspergillosis. The group has three products in the process of development; actimmune for the treatment of idiopathic pulmonary fibrosis, oritavancin, for the treatment of gram-positive bacterial infections and peg-infergen for the treatment of chronic hepatitis c infections. The major customers of the group include bergen brunswing, cardinal healthcare, caremark, merck medco, mckesson hboc and priority healthcare.
